Repare Therapeutics Inc. (RPTX)
NASDAQ: RPTX · IEX Real-Time Price · USD
3.810
-0.090 (-2.31%)
Jul 22, 2024, 11:37 AM EDT - Market open
Repare Therapeutics Employees
Repare Therapeutics had 179 employees as of December 31, 2023. The number of employees decreased by 1 or -0.56% compared to the previous year.
Employees
179
Change (1Y)
-1
Growth (1Y)
-0.56%
Revenue / Employee
$546,698
Profits / Employee
-$255,268
Market Cap
162.14M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 179 | -1 | -0.56% |
Dec 31, 2022 | 180 | 28 | 18.42% |
Dec 31, 2021 | 152 | 50 | 49.02% |
Dec 31, 2020 | 102 | 38 | 59.38% |
Dec 31, 2019 | 64 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Accuray | 1,024 |
OrganiGram Holdings | 984 |
Metagenomi | 236 |
Puma Biotechnology | 185 |
Rigel Pharmaceuticals | 147 |
Adverum Biotechnologies | 121 |
MediWound | 100 |
Syros Pharmaceuticals | 68 |
RPTX News
- 26 days ago - Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI - Business Wire
- 5 weeks ago - Foundation Medicine Announces Partnership with Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib - Business Wire
- 6 weeks ago - Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial - Business Wire
- 6 weeks ago - Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer - Business Wire
- 6 weeks ago - Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference - Business Wire
- 7 weeks ago - Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024 - Business Wire
- 2 months ago - Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results - Business Wire
- 2 months ago - Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition - Business Wire